uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Targeting TGF-beta Signaling in Cancer
Leiden Univ, Dept Mol Cell Biol, Canc Genom Ctr Netherlands, Med Ctr, Postbus 9600, NL-2300 RC Leiden, Netherlands..
Uppsala University, Science for Life Laboratory, SciLifeLab. Leiden Univ, Dept Mol Cell Biol, Canc Genom Ctr Netherlands, Med Ctr, Postbus 9600, NL-2300 RC Leiden, Netherlands.; Univ Tsukuba, Dept Canc Signaling, Fac Med, Tsukuba, Ibaraki 3058575, Japan..
2017 (English)In: TRENDS IN CANCER, ISSN 2405-8025, Vol. 3, no 1, p. 56-71Article, review/survey (Refereed) Published
Abstract [en]

The transforming growth factor (TGF)-beta signaling pathway is deregulated in many diseases, including cancer. In healthy cells and early-stage cancer cells, this pathway has tumor-suppressor functions, including cell-cycle arrest and apoptosis. However, its activation in late-stage cancer can promote tumorigenesis, including metastasis and chemoresistance. The dual function and pleiotropic nature of TGF-beta signaling make it a challenging target and imply the need for careful therapeutic dosing of TGF-beta drugs and patient selection. We review here the rationale for targeting TGF-beta signaling in cancer and summarize the clinical status of pharmacological inhibitors. We discuss the direct effects of TGF-beta signaling blockade on tumor and stromal cells, as well as biomarkers that can predict the efficacy of TGF-beta inhibitors in cancer patients.

Place, publisher, year, edition, pages
CELL PRESS , 2017. Vol. 3, no 1, p. 56-71
Keywords [en]
TGF-β, cancer, therapy resistance, microenvironment, tumor-initiating cells
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-351195DOI: 10.1016/j.trecan.2016.11.008ISI: 000425966200008PubMedID: 28718426OAI: oai:DiVA.org:uu-351195DiVA, id: diva2:1209019
Funder
Swedish Cancer SocietyAvailable from: 2018-05-21 Created: 2018-05-21 Last updated: 2018-05-21Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

ten Dijke, Peter

Search in DiVA

By author/editor
ten Dijke, Peter
By organisation
Science for Life Laboratory, SciLifeLab
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf